Favorable Outcome of Juvenile Dermatomyositis Treated without Systemic Corticosteroids

Deborah M. Levy, Catherine Bingham, Philip J. Kahn, Andrew H. Eichenfield, Lisa F. Imundo

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To describe the course of patients with juvenile dermatomyositis (JDM) treated effectively without systemic corticosteroids. Study design: A retrospective study of 38 patients with JDM treated at a tertiary care children's hospital identified 8 patients who had never received corticosteroids. Disease presentation and course, pharmacologic, and ancillary treatments were recorded. Results: Patients in the no corticosteroid group were followed for a median of 2.8 years (range, 2.1 to 9.5 years). Treatment was primarily with intravenous immunoglobulin (IVIG) (75%) and methotrexate (50%), with favorable response in all. No serious treatment complications were observed; headaches were reported by 3 patients receiving IVIG. Two patients had a myositis flare after discontinuing all medications for more than 1 year; complete resolution of symptoms was observed after either 1 or 2 further doses of IVIG. Two patients had calcinosis (at 1 and 9 years of disease); however, no patient had joint contractures, muscle atrophy, lipodystrophy, or functional limitations. Conclusions: Systemic corticosteroids can be avoided in a select group of patients with JDM. Alternative agents such as methotrexate and IVIG may be prescribed to effectively treat JDM and prevent complications.

Original languageEnglish (US)
Pages (from-to)302-307
Number of pages6
JournalJournal of Pediatrics
Volume156
Issue number2
DOIs
StatePublished - Feb 1 2010

Fingerprint

Adrenal Cortex Hormones
Intravenous Immunoglobulins
Methotrexate
Lipodystrophy
Juvenile dermatomyositis
Calcinosis
Myositis
Muscular Atrophy
Contracture
Tertiary Healthcare
Headache
Therapeutics
Retrospective Studies
Joints

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Levy, Deborah M. ; Bingham, Catherine ; Kahn, Philip J. ; Eichenfield, Andrew H. ; Imundo, Lisa F. / Favorable Outcome of Juvenile Dermatomyositis Treated without Systemic Corticosteroids. In: Journal of Pediatrics. 2010 ; Vol. 156, No. 2. pp. 302-307.
@article{0309f85361ae4ba987ac2783894fbf15,
title = "Favorable Outcome of Juvenile Dermatomyositis Treated without Systemic Corticosteroids",
abstract = "Objective: To describe the course of patients with juvenile dermatomyositis (JDM) treated effectively without systemic corticosteroids. Study design: A retrospective study of 38 patients with JDM treated at a tertiary care children's hospital identified 8 patients who had never received corticosteroids. Disease presentation and course, pharmacologic, and ancillary treatments were recorded. Results: Patients in the no corticosteroid group were followed for a median of 2.8 years (range, 2.1 to 9.5 years). Treatment was primarily with intravenous immunoglobulin (IVIG) (75{\%}) and methotrexate (50{\%}), with favorable response in all. No serious treatment complications were observed; headaches were reported by 3 patients receiving IVIG. Two patients had a myositis flare after discontinuing all medications for more than 1 year; complete resolution of symptoms was observed after either 1 or 2 further doses of IVIG. Two patients had calcinosis (at 1 and 9 years of disease); however, no patient had joint contractures, muscle atrophy, lipodystrophy, or functional limitations. Conclusions: Systemic corticosteroids can be avoided in a select group of patients with JDM. Alternative agents such as methotrexate and IVIG may be prescribed to effectively treat JDM and prevent complications.",
author = "Levy, {Deborah M.} and Catherine Bingham and Kahn, {Philip J.} and Eichenfield, {Andrew H.} and Imundo, {Lisa F.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1016/j.jpeds.2009.09.008",
language = "English (US)",
volume = "156",
pages = "302--307",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "2",

}

Favorable Outcome of Juvenile Dermatomyositis Treated without Systemic Corticosteroids. / Levy, Deborah M.; Bingham, Catherine; Kahn, Philip J.; Eichenfield, Andrew H.; Imundo, Lisa F.

In: Journal of Pediatrics, Vol. 156, No. 2, 01.02.2010, p. 302-307.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Favorable Outcome of Juvenile Dermatomyositis Treated without Systemic Corticosteroids

AU - Levy, Deborah M.

AU - Bingham, Catherine

AU - Kahn, Philip J.

AU - Eichenfield, Andrew H.

AU - Imundo, Lisa F.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Objective: To describe the course of patients with juvenile dermatomyositis (JDM) treated effectively without systemic corticosteroids. Study design: A retrospective study of 38 patients with JDM treated at a tertiary care children's hospital identified 8 patients who had never received corticosteroids. Disease presentation and course, pharmacologic, and ancillary treatments were recorded. Results: Patients in the no corticosteroid group were followed for a median of 2.8 years (range, 2.1 to 9.5 years). Treatment was primarily with intravenous immunoglobulin (IVIG) (75%) and methotrexate (50%), with favorable response in all. No serious treatment complications were observed; headaches were reported by 3 patients receiving IVIG. Two patients had a myositis flare after discontinuing all medications for more than 1 year; complete resolution of symptoms was observed after either 1 or 2 further doses of IVIG. Two patients had calcinosis (at 1 and 9 years of disease); however, no patient had joint contractures, muscle atrophy, lipodystrophy, or functional limitations. Conclusions: Systemic corticosteroids can be avoided in a select group of patients with JDM. Alternative agents such as methotrexate and IVIG may be prescribed to effectively treat JDM and prevent complications.

AB - Objective: To describe the course of patients with juvenile dermatomyositis (JDM) treated effectively without systemic corticosteroids. Study design: A retrospective study of 38 patients with JDM treated at a tertiary care children's hospital identified 8 patients who had never received corticosteroids. Disease presentation and course, pharmacologic, and ancillary treatments were recorded. Results: Patients in the no corticosteroid group were followed for a median of 2.8 years (range, 2.1 to 9.5 years). Treatment was primarily with intravenous immunoglobulin (IVIG) (75%) and methotrexate (50%), with favorable response in all. No serious treatment complications were observed; headaches were reported by 3 patients receiving IVIG. Two patients had a myositis flare after discontinuing all medications for more than 1 year; complete resolution of symptoms was observed after either 1 or 2 further doses of IVIG. Two patients had calcinosis (at 1 and 9 years of disease); however, no patient had joint contractures, muscle atrophy, lipodystrophy, or functional limitations. Conclusions: Systemic corticosteroids can be avoided in a select group of patients with JDM. Alternative agents such as methotrexate and IVIG may be prescribed to effectively treat JDM and prevent complications.

UR - http://www.scopus.com/inward/record.url?scp=74649086300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74649086300&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2009.09.008

DO - 10.1016/j.jpeds.2009.09.008

M3 - Article

C2 - 19846111

AN - SCOPUS:74649086300

VL - 156

SP - 302

EP - 307

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 2

ER -